美沙酮和丁丙诺啡可降低阿片类药物过量后的死亡风险

2018-06-24 MedSci MedSci原创

美国国立卫生研究院(NIH)资助的一项研究发现,在非致命性阿片类药物过量使用后,美沙酮或丁丙诺啡治疗显著降低了阿片类药物相关死亡率。

美国国立卫生研究院(NIH)资助的一项研究发现,在非致命性阿片类药物过量使用后,美沙酮或丁丙诺啡治疗显著降低了阿片类药物相关死亡率。

研究者分析了马萨诸塞州17,568名成年人在2012年至2014年间阿片类药物过量使用后幸存的数据。与那些未接受药物辅助治疗的患者相比,接受美沙酮治疗的阿片类药物过量死亡人数减少了59%。但由于样本量较小,作者无法得出有关美沙酮的结论,并指出需要进一步对较大样本开展工作。丁丙诺啡、美沙酮和纳曲酮是FDA批准用于治疗阿片类药物使用障碍(OUD)的三种药物,这项研究是首次探究丁丙诺啡、美沙酮和纳曲酮与非致命性阿片类药物过量所导致的死亡率之间的关系,这项大样本研究证实了之前关于美沙酮和丁丙诺啡可以有效治疗OUD预防死亡的结论。

尽管有令人信服的证据,尽管药物辅助治疗可以帮助许多人从阿片成瘾症中恢复过来,但这些已证实的药物仍然未被充分利用。该研究还发现,在服药过量后的第一年,只有不到三分之一的患者接受了药物治疗:美沙酮(11%)、丁丙诺啡(17%)、和纳曲酮(6%)。


原始出处:

https://www.europeanpharmaceuticalreview.com/news/76610/methadone-buprenorphine-opioid/

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032321, encodeId=30f1203232144, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jan 25 14:10:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253062, encodeId=9532125306282, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255775, encodeId=7f401255e75d4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309097, encodeId=12a4130909e8a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379520, encodeId=98c113e95202c, content=<a href='/topic/show?id=9f8be9968e3' target=_blank style='color:#2F92EE;'>#美沙酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79968, encryptionId=9f8be9968e3, topicName=美沙酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602814, encodeId=f149160281435, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032321, encodeId=30f1203232144, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jan 25 14:10:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253062, encodeId=9532125306282, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255775, encodeId=7f401255e75d4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309097, encodeId=12a4130909e8a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379520, encodeId=98c113e95202c, content=<a href='/topic/show?id=9f8be9968e3' target=_blank style='color:#2F92EE;'>#美沙酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79968, encryptionId=9f8be9968e3, topicName=美沙酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602814, encodeId=f149160281435, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032321, encodeId=30f1203232144, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jan 25 14:10:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253062, encodeId=9532125306282, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255775, encodeId=7f401255e75d4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309097, encodeId=12a4130909e8a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379520, encodeId=98c113e95202c, content=<a href='/topic/show?id=9f8be9968e3' target=_blank style='color:#2F92EE;'>#美沙酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79968, encryptionId=9f8be9968e3, topicName=美沙酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602814, encodeId=f149160281435, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2032321, encodeId=30f1203232144, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jan 25 14:10:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253062, encodeId=9532125306282, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255775, encodeId=7f401255e75d4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309097, encodeId=12a4130909e8a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379520, encodeId=98c113e95202c, content=<a href='/topic/show?id=9f8be9968e3' target=_blank style='color:#2F92EE;'>#美沙酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79968, encryptionId=9f8be9968e3, topicName=美沙酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602814, encodeId=f149160281435, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 lhlxtx
  5. [GetPortalCommentsPageByObjectIdResponse(id=2032321, encodeId=30f1203232144, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jan 25 14:10:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253062, encodeId=9532125306282, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255775, encodeId=7f401255e75d4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309097, encodeId=12a4130909e8a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379520, encodeId=98c113e95202c, content=<a href='/topic/show?id=9f8be9968e3' target=_blank style='color:#2F92EE;'>#美沙酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79968, encryptionId=9f8be9968e3, topicName=美沙酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602814, encodeId=f149160281435, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]
    2018-06-26 qblt
  6. [GetPortalCommentsPageByObjectIdResponse(id=2032321, encodeId=30f1203232144, content=<a href='/topic/show?id=e12f8e880fb' target=_blank style='color:#2F92EE;'>#药物过量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87880, encryptionId=e12f8e880fb, topicName=药物过量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Fri Jan 25 14:10:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253062, encodeId=9532125306282, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255775, encodeId=7f401255e75d4, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309097, encodeId=12a4130909e8a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379520, encodeId=98c113e95202c, content=<a href='/topic/show?id=9f8be9968e3' target=_blank style='color:#2F92EE;'>#美沙酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79968, encryptionId=9f8be9968e3, topicName=美沙酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602814, encodeId=f149160281435, content=<a href='/topic/show?id=94e819463d3' target=_blank style='color:#2F92EE;'>#丁丙诺啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19463, encryptionId=94e819463d3, topicName=丁丙诺啡)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e4218938219, createdName=xiaogang323, createdTime=Tue Jun 26 02:10:00 CST 2018, time=2018-06-26, status=1, ipAttribution=)]

相关资讯

NEJM:丁丙诺啡可用于治疗新生儿戒断综合征,比吗啡更好!

目前用吗啡治疗新生儿节戒断综合征,药物治疗持续时间较长且需住院治疗。对该适应症,丁丙诺啡可能比吗啡更有效。

Am J Obstet Gynecol:妊娠期丁丙诺啡给药频率应如何调整?

2017年10月,美国科学家在《Am J Obstet Gynecol》发表了增加妊娠期丁丙诺啡给药频率的循证推荐。

JAMA Pediatr:美国青少年阿片成瘾者药物治疗变化趋势

研究调查了青年阿片类物质成瘾患者接受药物干预的变化趋势以及影响因素,但仅有1/4的患者及时接受了药物治疗

JAMA:阿片类药物戒断治疗,丁丙诺啡舌下含服还是皮下植入?

由于服药依从性差、滥用和转移使得丁丙诺啡治疗阿片类药物依赖的效果十分有限。本研究旨在确定作为稳定戒断阿片类药物的依赖者的维持治疗使用丁丙诺啡植入剂治疗的效果是否劣于丁丙诺啡每日舌下含化的效果,治疗时间为6个月。2014年6月26日至2015年5月18日在美国 21个地区进行随机、活性对照、双盲双虚拟研究设计,纳入的研究对象为门诊患者。这些患者按处方每日舌下含服丁丙诺啡6个月及以上,每日舌下含服≤8

NEJM:丁丙诺啡治疗新生儿戒断综合征!

在新生儿戒断综合征的患儿中,舌下含服丁丙诺啡的治疗与口服吗啡相比,治疗时间更短,住院时间也缩短,而不良事件发生率相似。

JAMA Psychiatry:丁丙诺啡皮下埋植剂--CAM203用于阿片类药物依赖

每周24或32 mg的CAM2038具备较高的安全和耐受性并产生即时和持续的阿片戒断效果,该长效制剂有助于阿片类药物依赖的治疗减少传统剂型的不良反应